白癜风证治经验

目的：总结周宝宽主任医师辨证论治白癜风经验。方法：以医案的形式阐述白癜风的病因病机、证型、治法、方药。结果：白癜风的病因病机为禀赋不耐,感受外邪,阻滞经络,气血失和;情志内伤,肝气郁结,复感风邪,肌肤失养;禀赋不足,肝肾亏虚,久病失治或复感风邪,脉络瘀滞,肌肤失养。常见证型为气血失和、肝郁气滞、肝肾阴虚、气滞血瘀。常用治法为调和气血、疏肝理气、滋补肝肾、活血化瘀、祛风通络。结论：辨证论治白癜风有一定疗效。     

308nm准分子激光治疗稳定期白癜风的临床分析

目的 评估308 nm准分子激光局部照射治疗稳定期白癜风临床疗效及安全性.方法 采用准分子激光局部照射治疗125例共168处稳定期白癜风患者皮损,每周照射2～3次,治疗20次以上开始疗效评估,并记录不良反应.结果 125例共168处皮损白癜风患者经20次以上照射,显效率52.4%,有效率88.7%.面、颈项部和躯干部皮...     

Association between vitiligo and subsequent risk of dementia: A population‐based cohort study

Increasing evidence suggests a positive association between autoimmune disorders and the subsequent risk of dementia, supporting the idea that neuroinflammation is a major contributor to dementia. However, whether or not adults with vitiligo have an increased risk of dementia remains unclear. We aimed to investigate the association between vitiligo and the subsequent risk of dementia. A total of 1320 patients with vitiligo and 5280 matched controls were identified from the Taiwan National Health Insurance Research Database between 1998 and 2011. Dementia was diagnosed by board‐certificated psychiatrists or neurologists in the follow‐up period. Cox proportional hazards models were used to estimate the adjusted hazard ratios (aHR) after controlling for age, sex, income‐related monthly premium, residence and comorbidities associated with dementia. The incidence rate of dementia (per 100 000 person‐years) was 502.8 among patients with vitiligo and 101.9 among the controls. Patients with vitiligo were more likely to develop any type of dementia (aHR, 5.30; 95% confidence interval [CI], 3.30–8.51), Alzheimer’s disease (aHR, 12.22; 95% CI, 3.71–40.28) and vascular dementia (aHR, 3.99; 95% CI, 1.31–12.15) compared with the controls. In conclusion, middle‐aged and old patients with vitiligo are more likely to develop dementia compared with those without vitiligo. This novel finding reminds physicians to be more careful about signs of dementia when managing patients with vitiligo and provides the basis for further investigations that clarify the underlying mechanisms.     

The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomised clinical trials

There is currently no definitive treatment for vitiligo; various modalities include immune modulators phototherapy and skin camouflage. We investigated the efficacy and safety of topical tacrolimus either as monotherapy or combined therapy in the treatment of vitiligo. Electronic systematic search of the literature was carried out using four major databases. Randomised clinical trials (RCTs) that reported the use of topical tacrolimus in the treatment of human vitiligo have been included in a systematic review and meta-analysis. Meta-analysis was conducted via RevMan, and risk of bias was assessed through the Cochrane quality assessment tool. The protocol was published through PROSPERO (CRD42018112430). A total of 19 studies including 814 patients were included in our systematic review. The random-effects-model meta-analysis of two studies revealed that the tacrolimus and narrowband ultraviolet B (NB-UVB) combination therapy rates is better than NB-UVB alone in inducing >75% repigmentation [RR 1.34 (95% CI: 01.05–1.71), P = 0.02]. Tacrolimus and steroids had similar potency in acheiving >75% repigmentation [RR 1.02 (95% CI: 0.19–5.51), P = 0.98]. Meta-analysis of two studies revealed that the fractional laser and tacrolimus combination therapy is no better than tacrolimus alone in causing >75% repigmentation [RR 2.11 (95% CI: 0.87–5.09), P = 0.10]. Further investigating tacrolimus as mono- or adjuvant therapy for vitiligo is highly recommended. Combining tacrolimus to other treatment options such as steroids, phototherapy and laser may be superior to using tacrolimus alone.     

Vitiligo surgery: A journey from tissues via cells to the stems!

Depigmented patches in vitiligo, a common dermatosis, cause a great psychological distress to the patients. Hence, apart from halting the disease process, the strategies to impart normal skin colour to these white patches carry an important role in the management of vitiligo. Surgical procedures are often required for stable vitiligo lesions not responding to medical therapies. It involves “shuffling” of melanocytes from the pigmented skin to the depigmented areas. During the last fifty years, the vitiligo surgery has evolved from tissue transplantation via cellular transplantation to reach a stage where the use of stem cells or immunomodulatory cells is contemplating. We would like to depict this wonderful journey of vitiligo surgery through this viewpoint.     

火针联合卤米松乳膏治疗稳定期白癜风患者的疗效观察及对CD4+、CD8+、CD4+/CD8+水平的影响

 目的 观察火针联合卤米松乳膏治疗稳定期白癜风的临床疗效，检测对患者CD4⁺、CD8⁺及CD4⁺/CD8⁺水平的影响。方法 选择我院皮肤科及中医科门诊自2018年1月—2019年12月诊治的60例稳定期白癜风患者作为研究对象，随机分成对照组 (30例) 和试验组(30例)，对照组采用卤米松乳膏治疗，试验组予以火针联合卤米松乳膏治疗，比较两组患者治疗前后的白癜风面积评分指数(VASI),观察总有效率以及不良反应发生率。同时检测患者治疗前后CD4⁺、CD8⁺及 CD4⁺/CD8⁺的表达水平。结果两 组患者治疗前的VASI对比无显著差异(P＞0.05)。治疗后，试验组VASI明显低于对照组(9.73±0.56比10.79±1.13，t=4.60,P＜0.05），总有效率明显高于对照组(86.67%比63.33%,X²=4.36,P=0.037）。两组治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺均高于治疗前，试验组治疗后CD3+为(69.23±5.27)%，CD4⁺ 为(44.03±3.94)%,CD4⁺/CD8⁺比值为 (2.54±0.99)，对照组治疗后CD3⁺为(66.60±7.56)%，CD4⁺为(38.13±6.51)%, CD4⁺/CD8⁺比值为(1.91±0.87)，试验组各指标均高于对照组（均P＜0.05）；治疗后试验组CD8⁺为(19.30±5.55)%，低于对照组的(23.20±8.36)%，差异有统计学意义（P＜0.05）。结论 火针联合卤米松乳膏治疗不仅能有效促进稳定期白癜风患者皮肤恢复正常肤色，提高有效率，且能调节患者T淋巴细胞亚群，提高患者细胞免疫功能。因此火针是一种安全、高效的治疗方法，值得临床推广。